Program

27 NOVEMBER 2017

09:30 – Registration

10:00 – Welcome & Introduction

Welcome
Claude Leclerc and Salem Chouaib (Organizing Committee)

Introduction
Norbert Ifrah (Institut national du cancer, Boulogne-Billancourt)
Christine Chomienne (Aviesan’s Cancer Institute, Paris & Institut national du cancer, Boulogne-Billancourt)

10:30 – Keynote lecture : Giorgio Trinchieri (NIH-NCI, Bethesda)

Inflammation and tumor microenvironment

Chairmen : Jean-Yves Blay (Centre Léon Bérard, Lyon) and Alexander Eggermont (Gustave Roussy, Villejuif)

11:15 – Session 1 : Immune checkpoints and costimulatory molecules

Chairmen : Eric Vivier (CIML, Marseille) and Salem Chouaib (Gustave Roussy, Villejuif)

Melanoma serves as the model for solid tumors
Alexander Eggermont (Gustave Roussy, Villejuif)

Is there a place for ICI in the context of oncogenic addiction?
Jacques Cadranel (Hôpital Tenon, Paris)

Immunotherapy in kidney cancer: current situation and challenges
Bernard Escudier (Gustave Roussy, Villejuif)

12:45 – Lunch

14:15 – Introduction

Introduction
Yves Levy (Aviesan, Paris)

14:30 – Session 2 : Tumor microenvironment

Chairwoman/man : Catherine Sautès-Fridman (Centre de recherche des Cordeliers, Paris) and Vassili Soumelis (Institut Curie, Paris)

Hypoxia-inducible factors endow cancer cells with the capacity for tumor initiation and immune evasion
Gregg Semenza (John Hopkins University, Baltimore)

Combating immunosuppression in the tumor microenvironment
Benoit van den Eynde (Ludwig Institute for Cancer Research, Brussel)

Defining molecular identity of intratumoral T cells to design better cancer immunotherapies
Sergio Abrignani (INGM, Milan)

Chemotherapy and anti-cancer immune response: how to use cytotoxic agent to improve efficacy of immune-oncologic drugs?
François Ghiringhelli (Centre de Recherche Inserm-LNC, Dijon)

16:30 – Coffee Break

17:00 – Session 3 : Novel approaches to analyze tumor microenvironment

Chairmen: Daniel Olive (CRCM, Marseille) and Pierre Saintigny (CRCL, Lyon)

PD-L1 and associated biomarkers: What’s new and what’s next?
Janis Marie Taube (John Hopkins University, Baltimore)

Immune contexture and immunoscore in the era of cancer immunotherapy
Jérome Galon (Centre de recherche des Cordeliers, Paris)

18:00 – End of the first day

28 NOVEMBER 2017

08:30 – Registration & Welcome

09:00 – Keynote lecture : Carl H. June (Perelman School of Medicine, University of Pennsylvania)

T Cell therapy for Cancers

Chairmen : Eric Tartour (HEGP, Paris) and Jean-Christophe Bories (Hôpital Saint Louis, Paris)

09:45 – Session 4 : New cancer imaging tools

Chairwoman/man : Fathia Mami Chouaib (Gustave Roussy, Villejuif) and Jean-Jacques Fournié (Inserm, Toulouse)

Deciphering immune regulation within tumors
Sergio Quezada (UCL Cancer Institute, London)

Harnessing mutations for personalized cancer vaccine
Lelia Delamarre (GRME-South San Francisco)

10:45 – Coffee Break

11:15 – Session 5 : Cancer vaccines/Adoptive T cell immunotherapy/ Oncolytic viruses

Chairwoman/man : Claude Leclerc (Institut Pasteur, Paris) and Aurélien Marabelle (Gustave Roussy, Villejuif)

Chemotherapy to improve the therapeutic efficacy of cancer vaccines
Sjoerd van der Burg (Leiden University Medical Center, Leiden)

Precision T cell engineering to advance CAR therapy
Justin Eyquem (Memorial Sloan Kettering Cancer Center, New-York)

Translational development of the next generation of poxvirus-based immunotherapeutics
Eric Quemeneur (Transgène, Strasbourg)

12:45 – Lunch

14:00 – Session 6 : Targeting the tumor microenvironment for cancer immunotherapy

Chairwoman/man : Christophe Caux (CRCL, Lyon) and Lucie Peduto (Institut Pasteur, Paris)

Alteration of monocyte survival and immune dysfunctions in cancer
Vincenzo Bronté (VIMM, Padova)

Reprogramming the immunosuppressive tumor microenvironment
Michele De Palma (EPFL, Lausanne)

15:00 – Coffee Break

15:30 – Session 7 : Microbiota / Metabolism

Chairmen : François Valette (CRCNA, Nantes) and Marc Bonneville (Institut Mérieux, Lyon)

Tumor and host factors regulating anti-tumor immunity and immunotherapy efficacy
Thomas Gajewski (University of Chicago, Chicago)

The gut microbiome in cancer therapy
Laurence Zitvogel (Gustave Roussy, Villejuif)

Metabolic reprogramming enabling rapid CD8 T cell recall responses
Christoph Hess (University of Basel, Switzerland)

17:00 – Round table on latest discovery and development strategies in cancer immunotherapy

Chairwoman/men : Marc Bonneville, Lelia Delamarre and Eric Quemeneur

18:00 – Concluding remarks

Christine Chomienne, Claude Leclerc and Salem Chouaib